Rating Change
BMO Capital analysts initiated coverage on Perspective Therapeutics, Inc. (AMEX:CATX) with a rating of Outperform on August 19, 2026.
new coverageAMEX:CATX
BMO Capital Initiates Coverage on Perspective Therapeutics, Inc. (CATX) with Outperform
BMO Capital analysts initiated coverage on Perspective Therapeutics, Inc. (AMEX:CATX) with a rating of Outperform on August 19, 2026.
At publication ·
What changed
Perspective Therapeutics, Inc. (AMEX:CATX) · new coverage
- Firm
- BMO Capital
- Rating
- Outperform
- Price at event
- $3.21
- Market capitalization
- $200.3M
At a glance
Key takeaways
- BMO Capital initiated coverage of Perspective Therapeutics (CATX) with an Outperform rating on August 19, 2026.
- The stock trades at $3.21 with a market capitalization of $200.3 million and has declined 9.6% over the past 52 weeks.
Market Context
Perspective Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $3.21 with a market capitalization of $200.3M. The stock has declined 9.6% over the past 52 weeks.
Analyst coverage from BMO Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Perspective Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Perspective Therapeutics, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Outperform | N/A |
| Aug 14, 2026 | B of A Securities | Neutral | N/A |
| Aug 11, 2026 | Piper Sandler | Overweight | N/A |
| May 05, 2026 | Wedbush | Outperform | N/A |
| May 05, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CATX Stock Page
Frequently Asked Questions
What does the Outperform rating mean for CATX?
A rating of Outperform from BMO Capital reflects the analyst's outlook on Perspective Therapeutics, Inc. (AMEX:CATX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CATX forecast page.